Literature DB >> 12565984

Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma.

R Räty1, K Franssila, S-E Jansson, H Joensuu, U Wartiovaara-Kautto, E Elonen.   

Abstract

Approximately 20% of the mantle cell lymphoma (MCL) patients present with the blastoid variant at diagnosis. Blastoid changes may occur also during the course of the disease, but factors related to blastoid transformation are poorly understood. In the present study, the incidence and predictive factors for blastoid transformation were analysed among 52 patients who primarily had the common variant of MCL and one or more biopsies taken at the time of disease progression. Blastoid transformation occurred in 18 (35%) patients. The minimum estimated risk of transformation was 42% at 5 years of follow-up. At the time of transformation, all except two patients had systemic lymphoma with lymphatic blasts in the blood. The median survival time after blastoid transformation was 3.8 months compared with 26 months in patients without transformation (P<0.001). The respective survival times as calculated from the initial diagnosis of MCL were 31 and 60 months. Leucocytosis, an elevated serum lactate dehyrdogenase (LDH) level, and a high proliferative activity at diagnosis as assessed by the mitotic count and Ki-67 staining were associated with an increased risk of blastoid transformation, and elevated serum LDH and blood leucocytosis with a short time interval to transformation. We conclude that blastoid transformation is not uncommon during the course of MCL, and is associated with a poor outcome. An elevated serum LDH level, a high cell proliferation rate, and leucocytosis are predictive for a high risk of blastoid transformation in MCL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565984     DOI: 10.1016/s0959-8049(02)00456-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 2.  Mantle Cell Lymphoma: Which Patients Should We Transplant?

Authors:  James N Gerson; Stefan K Barta
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 3.  Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.

Authors:  Reza Setoodeh; Stuart Schwartz; Peter Papenhausen; Ling Zhang; Elizabeth M Sagatys; Lynn C Moscinski; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

4.  Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.

Authors:  Preetesh Jain; Shaojun Zhang; Rashmi Kanagal-Shamanna; Chi Young Ok; Krystle Nomie; Graciela Nogueras Gonzalez; Omarya Gonzalez-Pagan; Holly A Hill; Hun Ju Lee; Luis Fayad; Jason Westin; Loretta Nastoupil; Frederick Hagemeister; Wendy Chen; Onyeka Oriabure; Maria Badillo; Changying Jiang; Yao Yixin; Shaoying Li; Guilin Tang; C Cameron Yin; Keyur P Patel; Leonard Jeffrey Medeiros; Ranjit Nair; Sairah Ahmed; Swaminathan P Iyer; Selvi Thirumurthi; Richard Champlin; Guofan Xu; Pan Tinsu; David Santos; Ruiping Wang; Guangchun Han; Jianhua Zhang; Xingzhi Song; Sattva Neelapu; Jorge Romaguera; Andy Futreal; Christopher Flowers; Nathan Fowler; Linghua Wang; Michael L Wang
Journal:  Blood Adv       Date:  2020-03-24

Review 5.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15

6.  Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series.

Authors:  Joaquim Carreras; Naoya Nakamura; Rifat Hamoudi
Journal:  Healthcare (Basel)       Date:  2022-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.